Voluntary Qualified Importer Program; Guidance for Industry; Availability, 79502-79504 [2016-27252]
Download as PDF
79502
Federal Register / Vol. 81, No. 219 / Monday, November 14, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
August 29, 2016, a notice proposing to
permanently debar him from providing
services in any capacity to a person that
has an approved or pending drug
product application. The proposal was
based on a finding, under section
306(a)(2)(B) of the FD&C Act, that Mr.
Manookian was convicted of felonies
under Federal law for conduct relating
to the regulation of a drug product
under the FD&C Act. FDA determined
that Mr. Manookian’s felony convictions
were related to the regulation of drug
products because the conduct
underlying his convictions undermined
FDA’s regulatory oversight over drug
products marketed in the United
States—Mr. Manookian knowingly sold
unapproved drugs and put patients at
risk. The proposal also offered Mr.
Manookian an opportunity to request a
hearing, providing him 30 days from the
date of receipt of the letter in which to
file the request, and advised him that
failure to request a hearing constituted
a waiver of the opportunity for a hearing
and of any contentions concerning this
action. The proposal was received on
September 2, 2016. Mr. Manookian did
not request a hearing and has, therefore,
waived his opportunity for a hearing
and any contentions concerning his
debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Director, Office of
Enforcement and Import Operations,
Office of Regulatory Affairs, under
section 306(a)(2)(B) of the FD&C Act,
under authority delegated to him (Staff
Manual Guide 1410.35), finds that
Edward Manookian has been convicted
of felonies under Federal law for
conduct relating to the regulation of a
drug product under the FD&C Act.
Section 306(c)(2)(A)(ii) of the FD&C Act
requires that Mr. Manookian’s
debarment be permanent.
As a result of the foregoing finding,
Edward Manookian is permanently
debarred from providing services in any
capacity to a person with an approved
or pending drug product application
under section 505, 512, or 802 of the
FD&C Act (21 U.S.C. 355, 360b, or 382),
or under section 351 of the Public
Health Service Act (42 U.S.C. 262),
effective (see DATES) (see sections
201(dd) (21 U.S.C. 321(dd), 306(c)(1)(B),
and (c)(2)(A)(ii) of the FD&C Act). Any
person with an approved or pending
drug product application who
knowingly employs or retains as a
consultant or contractor, or otherwise
uses the services of Edward Manookian,
in any capacity during his debarment,
will be subject to civil money penalties
(section 307(a)(6) of the FD&C Act (21
U.S.C. 335b(a)(6))). If Mr. Manookian
VerDate Sep<11>2014
17:26 Nov 10, 2016
Jkt 241001
provides services in any capacity to a
person with an approved or pending
drug product application during his
period of debarment he will be subject
to civil money penalties (section
307(a)(7) of the FD&C Act). In addition,
FDA will not accept or review any
abbreviated new drug applications from
Edward Manookian during his period of
debarment (section 306(c)(1)(B) of the
FD&C Act).
Any application by Mr. Manookian
for special termination of debarment
under section 306(d)(4) of the FD&C Act
should be identified with Docket No.
FDA–2015–N–4169 and sent to the
Division of Dockets Management (see
ADDRESSES). All such submissions are to
be filed in four copies. The public
availability of information in these
submissions is governed by 21 CFR
10.20.
Publicly available submissions will be
placed in the docket, and will be
viewable at https://www.regulations.gov
or at the Division of Dockets
Management (see ADDRESSES) between 9
a.m. and 4 p.m., Monday through
Friday.
Dated: November 7, 2016.
Armando Zamora,
Deputy Director, Office of Enforcement and
Import Operations, Office of Regulatory
Affairs.
[FR Doc. 2016–27244 Filed 11–10–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0144]
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a
guidance for industry entitled ‘‘FDA’s
Voluntary Qualified Importer Program.’’
The guidance describes the Voluntary
Qualified Importer Program (VQIP),
which provides for expedited review
and importation of food offered for
importation by importers who
voluntarily agree to participate in the
program. The guidance describes the
eligibility criteria for, and benefits of,
participation in VQIP. The guidance
also provides information on submitting
an application for VQIP participation,
obtaining a facility certification for the
foreign supplier of a food imported
SUMMARY:
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed below (see ‘‘Written/
Paper Submissions’’ and
‘‘Instructions’’).
Written/Paper Submissions
Voluntary Qualified Importer Program;
Guidance for Industry; Availability
AGENCY:
under VQIP, the VQIP user fee,
conditions that might result in the
revocation of VQIP eligibility, and
criteria for reinstatement of eligibility.
DATES: Submit either electronic or
written comments on FDA guidances at
any time.
ADDRESSES: You may submit comments
as follows:
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2011–N–0144 for ‘‘FDA’s Voluntary
Qualified Importer Program.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
E:\FR\FM\14NON1.SGM
14NON1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 219 / Monday, November 14, 2016 / Notices
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for a single
hard copy of the guidance to the Office
of Enforcement and Import Operations
(ELEM–3108), Office of Regulatory
Affairs, Food and Drug Administration,
12420 Parklawn Dr., Element Bldg.,
Rockville, MD 20857. Send two selfaddressed adhesive labels to assist that
office in processing your request. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Office of
Enforcement and Import Operations
(ELEM–3108), Office of Regulatory
Affairs, Food and Drug Administration,
12420 Parklawn Dr., Element Bldg.,
Rockville, MD 20857, 301–796–0356.
VerDate Sep<11>2014
17:26 Nov 10, 2016
Jkt 241001
Regarding the information collection:
FDA PRA Staff, Office of Operations,
Food and Drug Administration, Three
White Flint North, 11601 Landsdown
St., 10A–12M, North Bethesda, MD
20852, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 302 of the FDA Food Safety
Modernization Act (FSMA) (Pub. L.
111–353) amended the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
by adding section 806, Voluntary
Qualified Importer Program (21 U.S.C.
384b). Section 806(a)(1) of the FD&C Act
directs FDA to establish a voluntary
program for the expedited review and
importation of food, and to establish a
process for the issuance of a facility
certification to accompany food offered
for importation by importers
participating in VQIP. Section 806(a)(2)
of the FD&C Act directs FDA to issue a
guidance document related to
participation in, revocation of such
participation in, reinstatement in, and
compliance with VQIP.
We are announcing the availability of
a guidance for industry entitled ‘‘FDA’s
Voluntary Qualified Importer Program.’’
We are issuing this guidance consistent
with our good guidance practices
regulation (21 CFR 10.115). The
guidance represents the current thinking
of FDA on this topic. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
In the Federal Register of June 5, 2015
(80 FR 32136), we made available a draft
guidance for industry on VQIP for
importers of human or animal food and
gave interested parties an opportunity to
submit comments by August 19, 2015,
for us to consider before beginning work
on the final version of the guidance. We
received numerous comments on the
draft guidance and have modified the
final guidance where appropriate.
Changes to the guidance include:
• Clarifying that, during the VQIP
fiscal year, a VQIP importer may add
additional food from a foreign supplier
from which the importer already
imports food under VQIP;
• clarifying that VQIP applicants will
not be required to upload food labels for
foods included in the VQIP application,
but FDA may request a copy of food
labels for the foods included in the
application to determine if there are
labeling violations relating to the risk of
the food during a VQIP inspection or
audit examinations;
• providing examples of how to
ensure that the Foreign Supplier
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
79503
Verification Program (FSVP) or the
Hazard Analysis and Critical Control
Point (HACCP) importer of the food
(when it is not the VQIP applicant) is in
compliance with the applicable FSVP or
HACCP regulations; and
• revising the ‘3-year import history’
eligibility criteria to provide for use of
shared importation history of previous
or parent companies.
We also made editorial changes and
changes to improve clarity. The
guidance announced in this notice
finalizes the draft guidance dated June
2015.
VQIP begins on January 1, 2018,
which is the first date FDA will begin
accepting applications to participate in
VQIP for the fiscal year 2019 beginning
October 1, 2018. We encourage food
importers with robust supplier
verification programs to apply for
participation in VQIP. We anticipate
that VQIP will allow FDA to focus its
resources on food shipments that pose
a higher risk to public health and will
facilitate risk-based admissibility
practices. We anticipate that we will
approve approximately 200 applications
for the first year of the program. We
established this limit based on
consideration of the demands on
Agency resources necessary to establish
and implement VQIP. We will review
applications in the order that we receive
them.
II. Paperwork Reduction Act of 1995
This guidance contains information
collection provisions that are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). Under the PRA, Federal Agencies
must obtain approval from OMB for
each collection of information they
conduct or sponsor. ‘‘Collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3 and includes
Agency requests or requirements that
members of the public submit reports,
keep records, or provide information to
a third party. Section 3506(c)(2)(A) of
the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information before submitting the
collection to OMB for approval. To
comply with this requirement, in the
Federal Register of June 5, 2015, we
gave interested persons 60 days to
comment on the information collection
provisions in the draft guidance (80 FR
32136 at 32138).
Currently FDA is finalizing the VQIP
application and will be submitting the
proposed collection for OMB review
and clearance under 44 U.S.C. 3507. An
E:\FR\FM\14NON1.SGM
14NON1
79504
Federal Register / Vol. 81, No. 219 / Monday, November 14, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. FDA is issuing this final
guidance subject to OMB approval of
the collection of information. Before the
Agency begins collecting information
for the VQIP program, FDA will publish
a notice in the Federal Register
announcing OMB’s decision to approve,
modify, or disapprove the information
collection provisions in the guidance.
The guidance also refers to previously
approved collections of information
found in FDA regulations. The
collections of information regarding
food labeling have been approved under
OMB control number 0910–0381; the
collections of information regarding
Low Acid Canned Food have been
approved under OMB control number
0910–0037; the collections of
information regarding Third-Party
Certification Bodies to Conduct Food
Safety Audits and to Issue Certifications
have been approved under OMB control
number 0910–0750; the collections of
information regarding Current Good
Manufacturing Practice and Hazard
Analysis and Risk-Based Preventive
Controls for Human Food have been
approved under OMB control number
0910–0751; the collections of
information regarding Current Good
Manufacturing Practice and Hazard
Analysis and Risk-Based Preventive
Controls for Food for Animals have been
approved under OMB control number
0910–0789; the collections of
information regarding the Foreign
Supplier Verification Program have
been approved under OMB control
number 0910–0752; the collections of
information regarding the Sanitary
Transportation of Human and Animal
Food have been approved under OMB
control number 0910–0773; and the
collections of information regarding
Focused Mitigation Strategies to Protect
Food Against Intentional Adulteration
have been approved under OMB control
number 0910–0812.
III. Electronic Access
Persons with access to the Internet
may obtain the guidance at either https://
www.fda.gov/RegulatoryInformation/
Guidances or https://
www.regulations.gov. Use the FDA Web
site listed in the previous sentence to
find the most current version of the
guidance.
IV. Other Issues for Consideration
FSMA directs FDA to collect user fees
to fund VQIP. Consistent with section
743(b)(2)(B)(iii) of the FD&C Act, we set
forth a proposed set of guidelines in
VerDate Sep<11>2014
17:26 Nov 10, 2016
Jkt 241001
consideration of the burden of user fee
amounts on small businesses in the
Federal Register of June 5, 2015 (80 FR
32136), which also announced the draft
guidance for industry on VQIP. We are
considering comments we received on
the VQIP user fee. We will publish the
actual fee in a Federal Register notice
in accordance with section 743(b)(1) of
the FD&C Act prior to the fiscal year
when we begin program benefits.
SUPPLEMENTARY INFORMATION:
Dated: November 7, 2016.
Leslie Kux,
Associate Commissioner for Policy.
OMB Control Number 0910–0458—
Extension
Under section 351 of the Public
Health Service Act (PHS Act) (42 U.S.C.
262), all biological products, including
human blood and blood components,
offered for sale in interstate commerce
must be licensed and meet standards,
including those prescribed in FDA
regulations, designed to ensure the
continued safety, purity, and potency of
such products. In addition under
section 361 of the PHS Act (42 U.S.C.
264), FDA may issue and enforce
regulations necessary to prevent the
introduction, transmission, or spread of
communicable diseases between the
States or possessions or from foreign
countries into the States or possessions.
Further, section 501 of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 351) provides that
drugs and devices (including human
blood and blood components) are
adulterated if they do not conform with
current good manufacturing practice
(CGMP) assuring that they meet the
requirements of the FD&C Act.
Establishments manufacturing
biological products, including human
blood and blood components, must
comply with the applicable CGMP
regulations (21 CFR parts 211, 606, and
820)) and current good tissue practice
(CGTP) regulations (part 1271 (21 CFR
part 1271)) as appropriate. FDA regards
biological product deviation (BPD)
reporting and human cells, tissues, and
cellular and tissue-based product (HCT/
P) deviation reporting to be an essential
tool in its directive to protect public
health by establishing and maintaining
surveillance programs that provide
timely and useful information.
Section 600.14 (21 CFR 600.14), in
brief, requires the manufacturer who
holds the biological product license, for
other than human blood and blood
components, and who had control over
a distributed product when the
deviation occurred, to report to the
Center for Biologics Evaluation and
Research (CBER) or to the Center for
Drugs Evaluation and Research (CDER)
as soon as possible but at a date not to
exceed 45 calendar days after acquiring
information reasonably suggesting that a
[FR Doc. 2016–27252 Filed 11–10–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0579]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Biological
Products: Reporting of Biological
Product Deviations and Human Cells,
Tissues, and Cellular and TissueBased Deviations in Manufacturing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(the PRA).
DATES: Fax written comments on the
collection of information by December
14, 2016.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0458. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
St., North Bethesda, MD 20852,
PRAStaff@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Biological Products: Reporting of
Biological Product Deviations and
Human Cells, Tissues, and Cellular and
Tissue-Based Product Deviations in
Manufacturing; Forms FDA 3486 and
3486A.
E:\FR\FM\14NON1.SGM
14NON1
Agencies
[Federal Register Volume 81, Number 219 (Monday, November 14, 2016)]
[Notices]
[Pages 79502-79504]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27252]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0144]
Voluntary Qualified Importer Program; Guidance for Industry;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing the
availability of a guidance for industry entitled ``FDA's Voluntary
Qualified Importer Program.'' The guidance describes the Voluntary
Qualified Importer Program (VQIP), which provides for expedited review
and importation of food offered for importation by importers who
voluntarily agree to participate in the program. The guidance describes
the eligibility criteria for, and benefits of, participation in VQIP.
The guidance also provides information on submitting an application for
VQIP participation, obtaining a facility certification for the foreign
supplier of a food imported under VQIP, the VQIP user fee, conditions
that might result in the revocation of VQIP eligibility, and criteria
for reinstatement of eligibility.
DATES: Submit either electronic or written comments on FDA guidances at
any time.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed below (see ``Written/Paper Submissions'' and
``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2011-N-0144 for ``FDA's Voluntary Qualified Importer Program.''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets
[[Page 79503]]
Management between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
Submit written requests for a single hard copy of the guidance to
the Office of Enforcement and Import Operations (ELEM-3108), Office of
Regulatory Affairs, Food and Drug Administration, 12420 Parklawn Dr.,
Element Bldg., Rockville, MD 20857. Send two self-addressed adhesive
labels to assist that office in processing your request. See the
SUPPLEMENTARY INFORMATION section for electronic access to the
guidance.
FOR FURTHER INFORMATION CONTACT: Regarding the guidance: Office of
Enforcement and Import Operations (ELEM-3108), Office of Regulatory
Affairs, Food and Drug Administration, 12420 Parklawn Dr., Element
Bldg., Rockville, MD 20857, 301-796-0356.
Regarding the information collection: FDA PRA Staff, Office of
Operations, Food and Drug Administration, Three White Flint North,
11601 Landsdown St., 10A-12M, North Bethesda, MD 20852,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 302 of the FDA Food Safety Modernization Act (FSMA) (Pub.
L. 111-353) amended the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) by adding section 806, Voluntary Qualified Importer Program (21
U.S.C. 384b). Section 806(a)(1) of the FD&C Act directs FDA to
establish a voluntary program for the expedited review and importation
of food, and to establish a process for the issuance of a facility
certification to accompany food offered for importation by importers
participating in VQIP. Section 806(a)(2) of the FD&C Act directs FDA to
issue a guidance document related to participation in, revocation of
such participation in, reinstatement in, and compliance with VQIP.
We are announcing the availability of a guidance for industry
entitled ``FDA's Voluntary Qualified Importer Program.'' We are issuing
this guidance consistent with our good guidance practices regulation
(21 CFR 10.115). The guidance represents the current thinking of FDA on
this topic. It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.
In the Federal Register of June 5, 2015 (80 FR 32136), we made
available a draft guidance for industry on VQIP for importers of human
or animal food and gave interested parties an opportunity to submit
comments by August 19, 2015, for us to consider before beginning work
on the final version of the guidance. We received numerous comments on
the draft guidance and have modified the final guidance where
appropriate. Changes to the guidance include:
Clarifying that, during the VQIP fiscal year, a VQIP
importer may add additional food from a foreign supplier from which the
importer already imports food under VQIP;
clarifying that VQIP applicants will not be required to
upload food labels for foods included in the VQIP application, but FDA
may request a copy of food labels for the foods included in the
application to determine if there are labeling violations relating to
the risk of the food during a VQIP inspection or audit examinations;
providing examples of how to ensure that the Foreign
Supplier Verification Program (FSVP) or the Hazard Analysis and
Critical Control Point (HACCP) importer of the food (when it is not the
VQIP applicant) is in compliance with the applicable FSVP or HACCP
regulations; and
revising the `3-year import history' eligibility criteria
to provide for use of shared importation history of previous or parent
companies.
We also made editorial changes and changes to improve clarity. The
guidance announced in this notice finalizes the draft guidance dated
June 2015.
VQIP begins on January 1, 2018, which is the first date FDA will
begin accepting applications to participate in VQIP for the fiscal year
2019 beginning October 1, 2018. We encourage food importers with robust
supplier verification programs to apply for participation in VQIP. We
anticipate that VQIP will allow FDA to focus its resources on food
shipments that pose a higher risk to public health and will facilitate
risk-based admissibility practices. We anticipate that we will approve
approximately 200 applications for the first year of the program. We
established this limit based on consideration of the demands on Agency
resources necessary to establish and implement VQIP. We will review
applications in the order that we receive them.
II. Paperwork Reduction Act of 1995
This guidance contains information collection provisions that are
subject to review by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). Under the
PRA, Federal Agencies must obtain approval from OMB for each collection
of information they conduct or sponsor. ``Collection of information''
is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3 and includes Agency
requests or requirements that members of the public submit reports,
keep records, or provide information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in the Federal Register concerning
each proposed collection of information before submitting the
collection to OMB for approval. To comply with this requirement, in the
Federal Register of June 5, 2015, we gave interested persons 60 days to
comment on the information collection provisions in the draft guidance
(80 FR 32136 at 32138).
Currently FDA is finalizing the VQIP application and will be
submitting the proposed collection for OMB review and clearance under
44 U.S.C. 3507. An
[[Page 79504]]
Agency may not conduct or sponsor, and a person is not required to
respond to, a collection of information unless it displays a currently
valid OMB control number. FDA is issuing this final guidance subject to
OMB approval of the collection of information. Before the Agency begins
collecting information for the VQIP program, FDA will publish a notice
in the Federal Register announcing OMB's decision to approve, modify,
or disapprove the information collection provisions in the guidance.
The guidance also refers to previously approved collections of
information found in FDA regulations. The collections of information
regarding food labeling have been approved under OMB control number
0910-0381; the collections of information regarding Low Acid Canned
Food have been approved under OMB control number 0910-0037; the
collections of information regarding Third-Party Certification Bodies
to Conduct Food Safety Audits and to Issue Certifications have been
approved under OMB control number 0910-0750; the collections of
information regarding Current Good Manufacturing Practice and Hazard
Analysis and Risk-Based Preventive Controls for Human Food have been
approved under OMB control number 0910-0751; the collections of
information regarding Current Good Manufacturing Practice and Hazard
Analysis and Risk-Based Preventive Controls for Food for Animals have
been approved under OMB control number 0910-0789; the collections of
information regarding the Foreign Supplier Verification Program have
been approved under OMB control number 0910-0752; the collections of
information regarding the Sanitary Transportation of Human and Animal
Food have been approved under OMB control number 0910-0773; and the
collections of information regarding Focused Mitigation Strategies to
Protect Food Against Intentional Adulteration have been approved under
OMB control number 0910-0812.
III. Electronic Access
Persons with access to the Internet may obtain the guidance at
either https://www.fda.gov/RegulatoryInformation/Guidances or https://www.regulations.gov. Use the FDA Web site listed in the previous
sentence to find the most current version of the guidance.
IV. Other Issues for Consideration
FSMA directs FDA to collect user fees to fund VQIP. Consistent with
section 743(b)(2)(B)(iii) of the FD&C Act, we set forth a proposed set
of guidelines in consideration of the burden of user fee amounts on
small businesses in the Federal Register of June 5, 2015 (80 FR 32136),
which also announced the draft guidance for industry on VQIP. We are
considering comments we received on the VQIP user fee. We will publish
the actual fee in a Federal Register notice in accordance with section
743(b)(1) of the FD&C Act prior to the fiscal year when we begin
program benefits.
Dated: November 7, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-27252 Filed 11-10-16; 8:45 am]
BILLING CODE 4164-01-P